EUVIMEDEUVIMED entdecken
Crossref

Targeting GSK-3β to Modulate the Wnt Pathway: A Promising Neuroprotective Strategy for Alzheimer’s Disease

Sai Varshini Magham iD, Shanooja Shanavas, Satya Sesha Sai Kiran S Pindiprolu, Krishnaveni Nagappan, Shubhangi More, Debajit Chaudhury, Aishwarya Reddy Ramakkamma, Madhu Tanya Singh, Ashish Wadhwani, Bipasha Bose, Praveen Thaggikuppe Krishnamurthy iD

Molecular Pharmaceutics · 03.11.2025 · 22 (11) · 6561-6574

DOI: 10.1021/acs.molpharmaceut.5c00329 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 15.10.2025. Verfasst von Sai Varshini Magham und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty 643001, TN, India. Hauptthemen laut MEDLINE: Alzheimer Disease, Neuroprotective Agents, Glycogen Synthase Kinase 3 beta, Indoles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is marked by amyloid-β plaques and neurofibrillary tangles. Glycogen synthase kinase-3β (GSK-3β) is a promising therapeutic target for mitigating several AD-related pathologies via modulation of the Wnt pathway. However, nonspecific GSK-3β inhibition by indirubin-3'-oxime (IMX) may result in significant off-target effects, necessitating the development of brain-targeted delivery systems. Solid lipid nanoparticles (SLNs) are biocompatible nanocarriers for brain-targeted delivery of therapeutics. Polysorbate 80 (PS80) and stearic acid (SA)-modified SLNs encapsulating IMX (PS80-SA SLNs-IMX) were prepared using the solvent injection method. The formula was optimized using full factorial design (FFD). The optimized formulation was biophysically characterized. The neuroprotective efficacy of PS80-SA SLNs-IMX was then evaluated in vitro using cell lines (IMR-32 & N2a). Biodistribution study was carried out in Wistar rats to evaluate the site-specific distribution of IMX and SLNs. The optimized PS80-SA SLNs-IMX exhibited a particle size of 185.7 ± 2.7 nm, a polydispersity index of 0.22 ± 0.01, a ζ potential of -21.02 ± 1.53 mV, and an entrapment efficiency of 99.4 ± 0.12%. Surface morphology analysis revealed that they are spherical in shape, and in vitro release study revealed the sustained release of PS80-SA SLNs-IMX until 48 h. Accelerated stability study results revealed the formulation stability with negligible changes in the PS, PDI, and ZP up to 6 months. MTT assay results have shown that PS80-SA SLNs-IMX has a negligible cytotoxic effect. ROS and neuroprotective assays have demonstrated antioxidant and neuroprotective effects of PS80-SA SLNs-IMX against OKA-induced neurotoxicity. ELISA depicted a significant reduction in Aβ1-42 and p-tau upon treatment with PS80-SA SLNs-IMX. Western blot analysis confirmed the effect of PS80-SA SLNs-IMX on the inhibition of GSK-3β and the activation of the Wnt pathway. Biodistribution study results revealed that PS80-SA SLNs-IMX has a significant increase in brain concentration when compared to naïve IMX, indicating the brain-specific distribution of PS80-SA SLNs-IMX. In conclusion, PS80-SA SLNs-IMX demonstrated enhanced neuronal cell uptake and significant neuroprotective activity in vitro. To our knowledge, this is the first report of PS80-SA SLNs-IMX with high entrapment and robust neuroprotection in an okadaic acid (OKA)-induced tauopathy model, underscoring the translational potential for AD therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseNeuroprotective AgentsGlycogen Synthase Kinase 3 betaIndolesWnt Signaling PathwayOximesAnimalsRatsNanoparticlesRats, WistarHumansMaleTissue DistributionBrainStearic AcidsCell Line, TumorDrug Delivery SystemsParticle SizeLiposomes

Stichwörter der Autor:innen

indirubin-3′-oximeneuroprotectiveokadaic acidpolysorbate 80

Substanzen

Neuroprotective AgentsGlycogen Synthase Kinase 3 betaIndolesOximesindirubin-3'-monoximeStearic Acidsstearic acidLipid NanoparticlesLiposomes

Autor:innen und Institutionen

  • Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty 643001, TN, India.
  • Stem Cells and Regenerative Medicine Centre, Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore, Karnataka575018, India.
  • Department of Pharmacology, School of Pharmacy, Aditya University, Surampalem 533437, India.
  • Department of Pharmaceutical Analysis, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty 643001, TN,India.
  • Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty 643001, TN, India.
  • Faculty of Health Sciences, School of Pharmacy, JSS Academy of Higher Education & Research, Vacoas-Phoenix 20201, Mauritius.

ORCID-Profile: Sai Varshini Magham, Praveen Thaggikuppe Krishnamurthy

Zitieren

APA

Magham, S. V., Shanavas, S., Pindiprolu, S. S. S. K. S., Nagappan, K., More, S., Chaudhury, D., Ramakkamma, A. R., Singh, M. T., Wadhwani, A., Bose, B., & Thaggikuppe Krishnamurthy, P. (2025). Targeting GSK-3β to Modulate the Wnt Pathway: A Promising Neuroprotective Strategy for Alzheimer’s Disease. Molecular Pharmaceutics, 22(11), 6561-6574. https://doi.org/10.1021/acs.molpharmaceut.5c00329

Vancouver

Magham SV, Shanavas S, Pindiprolu SSSKS, Nagappan K, More S, Chaudhury D, et al. Targeting GSK-3β to Modulate the Wnt Pathway: A Promising Neuroprotective Strategy for Alzheimer’s Disease. Molecular Pharmaceutics. 2025;22(11):6561-6574. doi:10.1021/acs.molpharmaceut.5c00329

BibTeX
@article{Magham2025,
  author = {Magham, Sai Varshini and Shanavas, Shanooja and Pindiprolu, Satya Sesha Sai Kiran S and Nagappan, Krishnaveni and More, Shubhangi and Chaudhury, Debajit and Ramakkamma, Aishwarya Reddy and Singh, Madhu Tanya and Wadhwani, Ashish and Bose, Bipasha and Thaggikuppe Krishnamurthy, Praveen},
  title = {Targeting GSK-3β to Modulate the Wnt Pathway: A Promising Neuroprotective Strategy for Alzheimer’s Disease},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  volume = {22},
  number = {11},
  pages = {6561--6574},
  doi = {10.1021/acs.molpharmaceut.5c00329}
}
Kostenlos starten →